Zydelig is a cancer medicine that is used to treat chronic lymphocytic leukaemia (CLL, a cancer of a type of white blood cells called B lymphocytes) and follicular lymphoma (another cancer that affects B lymphocytes). In CLL, Zydelig is used in combination with another medicine (rituximab or ofatumumab) in patients who have received at least one previous treatment and in patients whose cancer cells have genetic mutations (changes) called 17p deletion or TP53 mutation and who cannot be treated with any other therapy. In follicular lymphoma, Zydelig is used on its own in patients whose disease has not improved with two previous treatments. Zydelig contains the active substance idelalisib.
Therapeutic Indication
### Therapeutic indication Zydelig is indicated in combination with an anti?CD20 monoclonal antibody (rituximab or ofatumumab) for the treatment of adult patients with chronic lymphocytic leukaemia (CLL): - who have received at least one prior therapy, or - as first line treatment in the presence of 17p deletion or TP53 mutation in patients who are not eligible for any other therapies. Zydelig is indicated as monotherapy for the treatment of adult patients with follicular lymphoma (FL) that is refractory to two prior lines of treatment.
Therapeutic Area (MeSH)
ATC Code
L01XX47
ATC Item
xl 01 xx 47
Pharmacotherapeutic Group
N/A
Active Substance (Summary)
INN / Common Names
| Substance | CAS | Monograph |
|---|---|---|
| Idelalisib | N/A | 伊德利塞 |
EMA Name
Zydelig
Medicine Name
Zydelig
Aliases
N/ANo risk management plan link.
